Selective inhibitors for JNK signalling: a potential targeted therapy in cancer

• Published in: Journal of enzyme inhibition and medicinal chemistry 2020-01, Vol.35 (1), p.574-583
• Main Authors: Wu, Qinghua, Wu, Wenda, Jacevic, Vesna, Franca, Tanos C. C., Wang, Xu, Kuca, Kamil
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - chemical synthesis; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Breast cancer; c-Jun protein; cancer; Cancer therapies; cancer therapy; Cell Proliferation - drug effects; Cell survival; Cell Survival - drug effects; Humans; Isoforms; JNK; JNK Mitogen-Activated Protein Kinases - antagonists & inhibitors; JNK Mitogen-Activated Protein Kinases - metabolism; JNK protein; Lung cancer; Neoplasms - drug therapy; Neoplasms - metabolism; Neoplasms - pathology; Pancreas; Phosphorylation; Protein Kinase Inhibitors - chemical synthesis; Protein Kinase Inhibitors - chemistry; Protein Kinase Inhibitors - pharmacology; Review; selective inhibitors; Signal transduction; Signal Transduction - drug effects; SP60012; Transcription factors; Tumors; tumour
• ISSN: 1475-6366; 1475-6374
• DOI: 10.1080/14756366.2020.1720013

c-Jun N-terminal kinase (JNK) signalling regulates both cancer cell apoptosis and survival. Emerging evidence show that JNK promoted tumour progression is involved in various cancers, that include human pancreatic-, lung-, and breast cancer. The pro-survival JNK oncoprotein functions in a cell context- and cell type-specific manner to affect signal pathways that modulate tumour initiation, proliferation, and migration. JNK is therefore considered a potential oncogenic target for cancer therapy. Currently, designing effective and specific JNK inhibitors is an active area in the cancer treatment. Some ATP-competitive inhibitors of JNK, such as SP600125 and AS601245, are widely used in vitro; however, this type of inhibitor lacks specificity as they indiscriminately inhibit phosphorylation of all JNK substrates. Moreover, JNK has at least three isoforms with different functions in cancer development and identifying specific selective inhibitors is crucial for the development of targeted therapy in cancer. Some selective inhibitors of JNK are identified; however, their clinical studies in cancer are relatively less conducted. In this review, we first summarised the function of JNK signalling in cancer progression; there is a focus on the discussion of the novel selective JNK inhibitors as potential targeting therapy in cancer. Finally, we have offered a future perspective of the selective JNK inhibitors in the context of cancer therapies. We hope this review will help to further understand the role of JNK in cancer progression and provide insight into the design of novel selective JNK inhibitors in cancer treatment.